Market Tracker

05/26 8:21am ET

Novo Nordisk A/S (NYSE:NVO)

56.30
Delayed Data
As of May 25
 +1.33 / +2.42%
Today’s Change
46.17
Today|||52-Week Range
60.34
-3.06%
Year-to-Date
Novo Nordisk IDegLira Recommended by FDA Advisory Committee
May 25 / Zacks.com - Paid Partner Content
Businesses That Win Trait No. 3: Long-Term Thinking
May 24 / MotleyFool.com - Paid Partner Content
Sanofi Diabetes Drugs Briefing Documents Raise Concerns
May 24 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close54.97
Today’s open56.55
Day’s range56.15 - 56.59
Volume1,435,430
Average volume (3 months)1,498,783
Market cap$107.8B
Dividend yield1.70%
Data as of 05/25/2016

Growth & Valuation

Earnings growth (last year)+12.05%
Earnings growth (this year)--
Earnings growth (next 5 years)+12.35%
Revenue growth (last year)+1.43%
P/E ratio4.2
Price/Sales9.38
Price/Book20.49

Competitors

 Today’s
change
Today’s
% change
SNYSanofi+0.76+1.89%
GSKGlaxoSmithKline+0.41+0.96%
ABBVAbbVie+0.52+0.86%
BMYBristol-Myers Squibb-0.54-0.76%
Data as of 05/25/2016

Financials

Next reporting dateAugust 5, 2016
EPS forecast (this quarter)$0.59
Annual revenue (last year)$16.0B
Annual profit (last year)$5.2B
Net profit margin32.30%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
President &
Chief Executive Officer
Lars Rebien Sørensen
Chief Financial Officer &
Executive Vice President
Jesper Brandgaard
Corporate headquarters
Bagsværd, Capital Region

Forecasts